Antibody Therapeutics for Life

Notices

Bio Connection Australia 2019
  • Written by Admin
  • Written date 2019-07-01 13:08:50
  • Inquire 1818
Attachments Informa-Bio-Connections_PharmAbcine.pdf

PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo,

Chairman and Chief Executive Officer of PharmAbcine is invited as keynote speaker and panelist to give a presentation and panel discussion at Bio Connection Australia organized by INFORMA in Melbourne 

on August 19th-20th, 2019 

(https://www.informa.com.au/event/conference/bio-connections-australia/?utm_source=Web_PDF&utm_medium=PDF&utm_content=PDF&utm_campaign=P19A13 ) . 



Dr. Yoo will share the experience as follows:
1. Olinvacimab (previously Tanibirumab or TTAC-0001) Phase IIa with recurrent GBM trials completed on June 2017
(the last patient release) and completed with its CSR(Clinical Study Report) on March 2018.
2. Olinvacimab + Keytruda combo phase Ib with metastatic Triple Negative Breast Cancer ongoing trial.
3. Olinvacimab + Keytruda combo phase Ib with recurrent GBM ongoing trial. 

He also will share the preparation for next coming trials.

4. Olinvacimab phase II Avastin recurrent/relapsed recurrent GBM at Olivia Newton John Cancer Center in Melbourne joint trials with 
Stanford University Cancer Center and Florida Cancer Center in the States.
5.  Olinvacimab + Keytruda combo phase II with metastatic Triple Negative Breast Cancer global trial including Australia.
6.  Olinvacimab + Keytruda combo phase II with recurrent GBM global trial including Australia.  


Please check the attached file for details.

List





Prev KAIST ADVANCED BIO HEALTH INNOVATION PROGRAM
Next 2019 Scripps Korea Society Symposium